Gary S. Stetz insider trades

Open-market stock purchases and sales by Gary S. Stetz, Interim CEO at Hepion Pharmaceuticals, Inc, from SEC Form 4 filings since May 18, 2012.

Track record: 0% of 27 scored buys are up 5% or more since purchase, averaging -26%.

Recent trades

DateStockTradeValue
Aug 19, 2026HEPA Hepion Pharmaceuticals, IncBought (not open market)—
Aug 3, 2026HEPA Hepion Pharmaceuticals, IncBought$100K
Aug 3, 2026HEPA Hepion Pharmaceuticals, IncBought—
May 26, 2026CNTN Canton Strategic Holdings, IncSold$43.4K
May 22, 2026CNTN Canton Strategic Holdings, IncSold$44.2K
May 22, 2026CNTN Canton Strategic Holdings, IncSold$51.1K
May 22, 2026CNTN Canton Strategic Holdings, IncSold$34K
Apr 21, 2026HEPA Hepion Pharmaceuticals, IncBought$50K
Nov 3, 2025THAR Tharimmune, IncBought (not open market)—

Companies traded

  • HEPA Hepion Pharmaceuticals, Inc: 3 buys, last Aug 19, 2026
  • CNTN Canton Strategic Holdings, Inc: 4 sales, last May 26, 2026
  • THAR Tharimmune, Inc: other filings, last Nov 3, 2025
  • BCBP BCB Bancorp Inc: 28 buys, last Mar 14, 2018

Get free alerts when Gary S. Stetz files a new trade →